Revolution Medicines Inc. | Mid-cap | Healthcare
$36.89
0.27%
| Revolution Medicines Stock Comparison:
Revolution Medicines vs VertexRevolution Medicines vs RegeneronRevolution Medicines vs Blueprint MedicinesRevolution Medicines vs Roivant SciencesRevolution Medicines vs Bio-TechneRevolution Medicines vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -689.5M
Net Income -600.1M
EPS (Diluted) -$3.58

Balance Sheet Metrics

Total Assets 2.6B
Total Liabilities 293.1M
Shareholders Equity 2.3B
Debt to Equity 0.13

Cash Flow Metrics

Operating Cash Flow -521.0M
Free Cash Flow -567.7M

Revenue & Profitability Trend

Revolution Medicines Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 0 11.6M 35.4M 29.4M 43.0M
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Research & Development 592.2M 423.1M 253.1M 186.9M 132.3M
Selling, General & Administrative 97.3M 75.6M 40.6M 30.4M 21.4M
Other Operating Expenses 0 -11.6M -35.4M -29.4M -43.0M
Total Operating Expenses 689.5M 487.2M 258.3M 188.0M 110.7M
Operating Income -689.5M -487.2M -258.3M -188.0M -110.7M
Pre-tax Income -600.8M -439.9M -249.1M -187.1M -108.5M
Income Tax -753.0K -3.5M -420.0K 0 -371.0K
Net Income -600.1M -436.4M -248.7M -187.1M -108.2M
EPS (Diluted) -$3.58 -$3.86 -$3.08 -$2.57 -$2.01

Income Statement Trend

Revolution Medicines Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 2.3B 1.9B 660.2M 589.8M 454.1M
Non-Current Assets 230.7M 182.4M 151.7M 148.2M 113.3M
Total Assets 2.6B 2.1B 811.9M 738.0M 567.4M
Liabilities
Current Liabilities 163.9M 143.9M 62.0M 60.4M 47.2M
Non-Current Liabilities 129.2M 91.7M 64.8M 75.1M 45.5M
Total Liabilities 293.1M 235.5M 126.7M 135.4M 92.7M
Equity
Total Shareholders Equity 2.3B 1.8B 685.2M 602.6M 474.7M

Balance Sheet Composition

Revolution Medicines Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -600.1M -436.4M -248.7M -187.1M -108.2M
Operating Cash Flow -521.0M -340.6M -219.1M -159.2M -104.0M
Investing Activities
Capital Expenditures -10.3M -7.7M -10.8M -6.5M -2.9M
Investing Cash Flow -554.4M -342.6M -24.1M -142.1M -234.2M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 846.6M 1.2B 298.1M 290.8M 420.1M
Free Cash Flow -567.7M -358.3M -235.2M -153.7M -103.0M

Cash Flow Trend

Revolution Medicines Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -11.18
Forward P/E -9.89
Price to Book 3.59
PEG Ratio -9.89

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -36.68%
Return on Assets -23.09%

Financial Health

Current Ratio 13.46
Debt to Equity 6.46
Beta 1.10

Per Share Data

EPS (TTM) -$4.01
Book Value per Share $11.16
Revenue per Share $0.00

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
rvmd 7.5B -11.18 3.59 -36.68% 0.00% 6.46
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99

Financial data is updated regularly. All figures are in the company's reporting currency.